Baird Capital Invests in Cala Health, Inc.

Cala Trio

Cala Health, Inc. (Cala) announced today that is has raised $50 Million Series C Funding from a number of new investors, including Baird Capital.

Cala is a bioelectronic medicine company developing wearable therapies for chronic disease. They will use the new funds to introduce Cala TrioTM, a breakthrough therapy for hand tremors in people with essential tremor, to the market as well as expand its therapeutic pipeline.

Read Cala’s news release for more information.